MORRISVILLE, N.C.--(Aerocrine AB (OMX Nordic Exchange: AERO), a medical technology company focused on the improved management and care of patients with inflammatory airway diseases , today announced it will host a grand opening celebration at its new US headquarters in Morrisville, N.C.)--
“Aerocrine is proud to become a member of the Triangle community as we continue to advance the use of our technology in the US market.”
The company is based in Sweden with subsidiaries in Germany and the UK, in addition to the US. Aerocrine relocated its North American headquarters to Morrisville this spring, with plans to expand its local workforce in the coming years.
“With some of the most well respected educational institutions and healthcare companies in the state, North Carolina is at the cutting edge of respiratory disease research and therapy development,” says Aerocrine President Ken Marshall. “Aerocrine is proud to become a member of the Triangle community as we continue to advance the use of our technology in the US market.”
Aerocrine is the developer of the NIOX MINO® device which measures fractional exhaled nitric oxide (FeNO) for asthma research and clinical applications. NIOX MINO® is intended for routine measurements, where it can be used to improve the management of asthma and other inflammatory airway conditions in both specialist and primary care clinics.
“We are pleased to welcome Aerocrine to the Triangle community,” says Morrisville Mayor Jackie Holcombe. “Aerocrine brings a rich history of innovation to the region and furthers our standing as one of the leading healthcare research communities in the country.”
The grand opening event will take place on Thursday, September 20, beginning at noon with a ribbon cutting and opening remarks by local government and Aerocrine management. A traditional, North Carolina barbeque lunch, series of roundtable discussions, and tour of the facility will follow.
Aerocrine and its Board of Directors will be joined by Morrisville Mayor Jackie Holcombe, as well as town council members, and representatives of both the North Carolina Biotech Center and Morrisville Chamber of Commerce.
For more information on Aerocrine’s grand opening event, please contact email@example.com.
Aerocrine AB (publ.) is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine’s shares were listed on the Stockholm Stock Exchange on 15 June 2007.